- The FDA has approved Merck & Co Inc's MRK Keytruda, an anti-PD-1 therapy, for the adjuvant treatment of renal cell carcinoma (RCC).
- The news comes almost half a year after Merck took the stage at ASCO to report Phase 3 data showing Keytruda cut the risk of cancer relapse or death by 32% compared to placebo, hitting the primary endpoint of disease-free survival.
- The study, dubbed KEYNOTE-564, enrolled 994 RCC patients at intermediate-high or high risk of recurrence after a kidney removal or after removal of a kidney and metastatic lesions.
- The trial will continue to assess overall survival (OS) as a secondary outcome measure.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: MRK shares are down 0.06% at $82.55 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
